Regencell Bioscience Holdings (NasdaqCM:RGC) - Share price, News & Analysis

RGC fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

RGC Stock Overview

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company.

Risk Analysis

Makes less than USD$1m in revenue ($0)

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

Regencell Bioscience Holdings Competitors

Tarsus Pharmaceuticals

NasdaqGS:TARS

US$463.6m

Verona Pharma

NasdaqGM:VRNA

US$605.5m

Jushi Holdings

OTCPK:JUSH.F

US$391.7m

Ocular Therapeutix

NasdaqGM:OCUL

US$377.9m

Price History & Performance

Summary of all time highs, changes and price drops for Regencell Bioscience Holdings
Historical stock prices
Current Share Price	US$32.14
52 Week High	US$59.00
52 Week Low	US$6.00
Beta	0
1 Month Change	-15.42%
3 Month Change	32.70%
1 Year Change	257.11%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	206.10%

Shareholder Returns

	RGC	US Pharmaceuticals	US Market
7D	-1.6%	-0.8%	0.3%
1Y	257.1%	1.5%	-13.5%

Return vs Industry: RGC exceeded the US Pharmaceuticals industry which returned 2% over the past year.

Return vs Market: RGC exceeded the US Market which returned -13% over the past year.

Price Volatility

Is RGC's price volatile compared to industry and market?
RGC volatility
RGC Average Weekly Movement	13.0%
Pharmaceuticals Industry Average Movement	11.7%
Market Average Movement	7.9%
10% most volatile stocks in US Market	17.2%
10% least volatile stocks in US Market	3.2%

Stable Share Price: RGC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: RGC's weekly volatility has decreased from 44% to 13% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2014	14	Yat-Gai Au	https://www.regencellbioscience.com

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Regencell Bioscience Holdings Fundamentals Summary

How do Regencell Bioscience Holdings's earnings and revenue compare to its market cap?
RGC fundamental statistics
Market Cap	US$418.23m
Earnings (TTM)	-US$4.60m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-90.8x

P/E Ratio

Is RGC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
RGC income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$4.60m
Earnings	-US$4.60m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.35
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	6.9%

How did RGC perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is RGC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RGC?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for RGC. This is calculated by dividing RGC's market cap by their current preferred multiple.
What is RGC's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$418.23m

RGC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-90.3x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does RGC's PB Ratio compare to its peers?

RGC PB Ratio vs Peers

The above table shows the PB ratio for RGC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PB	Estimated Growth	Market Cap
Peer Average	3.9x
TARS Tarsus Pharmaceuticals	3.1x	53.2%	US$463.6m
VRNA Verona Pharma	4.8x	56.7%	US$605.5m
JUSH.F Jushi Holdings	1.9x	-40.3%	US$391.7m
OCUL Ocular Therapeutix	5.7x	62.7%	US$377.9m
RGC Regencell Bioscience Holdings	21.2x	n/a	US$418.2m

Price-To-Book vs Peers: RGC is expensive based on its Price-To-Book Ratio (21.2x) compared to the peer average (3.9x).

Price to Earnings Ratio vs Industry

How does RGC's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Book vs Industry: RGC is expensive based on its Price-To-Book Ratio (21.2x) compared to the US Pharmaceuticals industry average (2x)

Price to Book Ratio vs Fair Ratio

What is RGC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RGC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	21.2x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate RGC's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of RGC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RGC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RGC's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Regencell Bioscience Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

10.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Regencell Bioscience Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Take a look at our analysis of RGC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Past Performance

How has Regencell Bioscience Holdings performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-442.8%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: RGC is currently unprofitable.

Growing Profit Margin: RGC is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if RGC's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare RGC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RGC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).

Return on Equity

High ROE: RGC has a negative Return on Equity (-23.72%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Regencell Bioscience Holdings's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: RGC's short term assets ($19.0M) exceed its short term liabilities ($1.4M).

Long Term Liabilities: RGC has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: RGC's net debt to equity ratio (6.6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if RGC's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if RGC has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if RGC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies

Dividend

What is Regencell Bioscience Holdings's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate RGC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RGC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RGC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RGC's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RGC has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure

CEO

Yat-Gai Au (49 yo)

no data

Tenure

Mr. Yat-Gai Au serves as the Chief Financial Officer of Armitage Technologies Holding Ltd. Mr. Au served as Compliance Officer and Executive Director of Armitage Technologies Holding Ltd. He joined Armitag...

Leadership Team

Experienced Management: RGC's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.

Board Members

Experienced Board: RGC's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: RGC insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.

Data	Last Updated (UTC time)
Company Analysis	2022/08/09 00:00
End of Day Share Price	2022/08/09 00:00
Earnings	2021/12/31
Annual Earnings	2021/06/30